Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review
- 18 February 2023
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 184, 83-105
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- A systematic review examining factors influencing health related quality of life among melanoma cancer survivorsEuropean Journal of Cancer, 2016
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyAnnals of Oncology, 2016
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialThe Lancet Oncology, 2015
- Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaEuropean Journal of Cancer, 2015
- Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineAnnals of Oncology, 2014
- Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyAnnals of Oncology, 2014
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatmentHealth and Quality of Life Outcomes, 2012
- Assessment of Patient-Reported Outcomes in Patients with MelanomaSurgical Oncology Clinics of North America, 2011
- A systematic review of health-related quality of life in cutaneous melanomaAnnals of Oncology, 2009
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II TrialsJournal of Clinical Oncology, 2008